NCT04412304View on ClinicalTrials.gov

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

CompletedOBSERVATIONAL
Enrollment

166

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

May 28, 2020

Conditions
Covid-19Thromboembolic EventsBleeding
Interventions
DRUG

Dose of Tinzaparin or Dalteparin

The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.

Trial Locations (1)

11880

South General Hospital, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT04412304 - Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients | Biotech Hunter | Biotech Hunter